Home
NGHIÊN CỨU LÂM SÀNG
Issue: Số 69 (2015)
Article
Cao Trường Sinh: Trường Đại học Y khoa Vinh;
Nguyễn Thị Thúy Ngân: Trường Đại học Y khoa Vinh;
Published: April 1, 2015
Views: 66
References
1.
1. Harold P. Adams, Lawrence Brass, Anthony Furlan et al (2007), Guidelines for the Early Management of Adults With Ischemic Stroke, AHA/ASA Guidelines, p 1655-1693.
2.
2. Vivencio Barrios et al (2002), Antihypertension Efficacy and Tolerability of Lercanidipine in Daily Clinical Practice. The ELYPSE Study, Blood Pressure 2002, Vol 11, p 95-100.
3.
3. Barrios et al (2006), Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA Study, Journal Clinical Practice, 60,11:1364-1370
4.
4. Norm Campbell et al (2010), Canadian Hypertension Education Program recommendations, An annual update, Canadian Family Physician- Le Medecin de famille canadien, p 649-653.
5.
5. Campo et al (2005), Correlations of smoothness index and trough-to-peak ratio with left ventricular mass index changes induced by lercanidipine in hypertensive patient, Minerva Med, 96 (5): 365-371.
6.
6. Flack J.M, Nasser SA (2011), Benefits of once-daily therapies in the treatmment of hypertension, Vase Health Risk Manag 2011; 7:777-787
7.
7. Goda. A et al (2010), Comparative effects of lercanidipine and amlodipine in treatment of mild to moderate hypertension, Journal of Hypertension, vol 28, e-Supplement A, p 277-278.
8.
8. Hernandez RH and al (2001), Comparative effects of amlodipine and nifedipine GITS during treatment and after missing two doses, Blood Press Monit 2001, 6(1):47-57.
9.
9. Iqbal. P and Louise Stevension (2011), Cardiovascular Outcomes in patients with normal and abnormal 24-hour ambulatory blood pressure monitoring, International Journal of Hypertension, 4 pages.
10.
10. Yuan Jiao et al(2012), Reduction of the morning blood pressure surge treated with Olmesartan in Chinese patients with mild to moderate essential hypertension- a multicenter, open-label, single treatment group clinical study, European Review for Medical and Pharmacological Sciences, 16: 653-659.
11.
11. Gastone Leonetti et al (2002), Tolerability of Long- Term Treatment With Lercanidipine Versus Amlodipine and Lacidipine in Elderly Hypertensives, American Journal of Hypertension, Vol 15, p 932-940.
12.
12. Joel M. Neutel and David H.G. Smith (2003), Evaluation of Angiotensin II Receptor Blockers for 24- Hour Blood Pressure Control: Meta- Analysis of a Clinical Database, the journal of hypertension; Vol V, No 1: 58-63
13.
13. Omboni S, Zanchetti A (1998), Antihypertension efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensive assessed by clinic and ambulatory blood pressure measurements. Multicenter Study Investigators, Journal Hypertens 1998, 16:1831-1838.
14.
14. Narakin Sansanayudh et al (2010), Comparison of Changes of Body Water Measured by Using Bioelectrical Impedance Analysis between Lercanidipine and Amlodipine Therapy in Hypertensive Outpatients, J Med Assoc Thai, Vol 93 Suppl, p 84-92.
15.
15. Thomas Truelsen et al (2000), Global burden of cerebrovascular disease, Cerebrovascular diseases, p 1-67.
16.
16. WHO/ISH (2003), “Statement on management of Hypertension”, Journal of Hypertesion 2003, 21(11); 1983-1992.